Dongyang Pharmaceutical (06887) filed a record with the China Securities Regulatory Commission regarding plans to implement full circulation of H shares

Zhitong Finance App News, Dongyang Pharmaceutical (06887) issued an announcement. On September 23, 2026, the Company submitted a filing application (application) to the China Securities Regulatory Commission for the conversion of 389.217 million domestic shares held by the Company's shareholders to the Company's H shares, accounting for about 6.75% of the total issued share capital of the Company on the date of this announcement (full circulation of H shares).

After obtaining all relevant approvals (including filing with the China Securities Regulatory Commission and approval of the Stock Exchange) and complying with all applicable laws, rules and regulations, the relevant domestic shares will be converted to H shares, and the Company will apply to the Stock Exchange for listing and trading (conversion and listing) of such H shares on the main board of the Stock Exchange.

According to the company's articles of association and applicable Chinese law, the company is not required to hold a shareholders' meeting to approve the full circulation, conversion and listing of H shares.

As of the date of this announcement, the Company's application has not been accepted by the China Securities Regulatory Commission, and the execution details of the conversion and listing plans have not yet been implemented. The Company will make further announcements on the full circulation of H shares and the progress of conversion and listing in due course in accordance with the requirements of the listing rules.